IFF Expands Partnership with Kemira to Commercialize New Designed Enzymatic Biomaterials
- DEB technology platform enables the production of renewable polymers with high performance and improved sustainability profile
- New biomanufacturing facility in Finland to be operational in mid-2024
- Addresses growing demand for alternatives to traditional fossil-based synthetic polymers in various markets
- None.
Insights
Emerging biopolymers technology represents a significant stride in sustainable materials science. The collaboration between IFF and Kemira, focusing on the commercialization of renewable polymers, addresses a critical market need for environmentally friendly alternatives to traditional fossil-based synthetic polymers. The integration of IFF's Designed Enzymatic Biomaterials (DEB) technology into industrial-scale production is a notable advancement in the pulp, paper, packaging and water treatment industries.
The transition to biopolymers is poised to offer long-term environmental benefits, such as reduced reliance on non-renewable resources and improved end-of-life material properties, including recyclability and biodegradability. This aligns with global sustainability goals and the increasing consumer demand for 'green' products. However, the scalability of production and the economic viability of these new materials will be critical in determining their market penetration and potential impact on IFF and Kemira's financial performance.
For stakeholders, the potential benefits include enhanced corporate reputation, alignment with regulatory trends favoring sustainability and the opening of new market opportunities. Risks involve the initial high costs associated with research and development, potential market resistance due to existing supply chains for traditional materials and the need for extensive marketing efforts to educate consumers and industries on the advantages of these new materials.
The announcement of IFF and Kemira's collaboration to scale up renewable polymers production has implications for both companies' financial outlooks. The ability to meet the growing demand for sustainable materials could lead to new revenue streams and diversification of their product portfolios. The integration of the biomanufacturing facility within Chemigate Ltd's biorefinery indicates a strategic move to optimize production efficiency and reduce costs.
Investors should monitor the adoption rate of these biopolymers in the targeted industries, as it will be a critical determinant of the venture's success. The initial investment into the facility and technology development may pressure short-term earnings, but the long-term payoff could be substantial if the market for sustainable materials continues to expand. Moreover, the companies may benefit from potential subsidies or tax incentives aimed at promoting sustainability.
It is essential to compare the performance of these biopolymers with existing products to assess their competitive edge. Any sign of superior performance or cost-effectiveness could significantly influence market share dynamics and, consequently, the financial performance of both IFF and Kemira.
The strategic partnership between IFF and Kemira to produce high-performance biopolymers at an industrial scale is a testament to the growing trend of bio-based solutions in the materials industry. The integration of the DEB technology into Chemigate Ltd's biorefinery is expected to streamline production and potentially set a new industry standard for sustainable material manufacturing.
From an industry perspective, this move could catalyze a broader shift towards renewable materials, influencing supply chains and production methods across multiple sectors. The success of this venture could encourage other companies to invest in similar technologies, thereby accelerating the industry's transition to a more circular economy. However, the rate of adoption will depend on the cost-competitiveness and performance of these biopolymers compared to traditional materials.
Competitors in the materials sector will need to closely observe this development and may need to adapt their strategies accordingly to remain competitive. For the pulp, paper and water treatment industries, in particular, this could signify a significant shift in material sourcing and product design, with sustainability becoming a more prominent factor in consumer choice.
High-performance biopolymers will soon be available for use at industrial scale, contributing to a more circular economy with new renewable materials
The IFF-Kemira collaboration addresses Kemira's growing demand for alternatives to traditional fossil-based synthetic polymers across pulp, paper, and paper-based packaging markets and in industrial and municipal water treatment sectors. This follows Kemira's advances in application development programs, particularly in strength, dewatering, and barrier applications.
IFF's DEB technology was launched earlier in 2023 for use in home and personal care markets. By expanding the application and commercialization of its DEB technology, IFF's customers will now have access to the new product lines of high-performance material solutions that promote a circular bioeconomy at a sufficient scale for industrial use. This will enable IFF to commercially supply lead customers and support strategic application development programs at scale. These materials expand IFF's AURIST™ biopolymers for personal care applications, and IFF's Nuvolve® engineered polysaccharides for industrial applications.
"In today's world, innovation must go hand-in-hand with sustainability," said Christian Lenges, IFF venture director. "It is a topic of conversation at nearly every customer meeting. For years, 'green' products were deemed inferior in performance to fossil-based alternatives, but this is no longer the case. We are proud to leverage our bioscience knowledge to develop the DEB technology platform, allowing us to provide the first commercial quantities for our partners and customers."
"This is a major step in our growth strategy implementation and our journey to build a leading renewable materials portfolio," said Sampo Lahtinen, SVP growth accelerator, Kemira Oyj. "This cutting-edge biotechnology platform enables the production of renewable polymers, which combine high performance with significant improvements in the sustainability profile, including end-of-life properties such as recyclability and biodegradability. We are excited to scale up new alternatives to fossil-based products without compromising performance and competitiveness."
"We're pleased to support IFF and Kemira with material biomanufacturing integrated at our biorefinery at Finnamyl, with the aim of driving positive change across a range of industries," said Tom Schauman, CEO, Chemigate. "Manufacturers will now have access to commercially relevant quantities of IFF's Designed Enzymatic Biomaterials, to improve sustainability across a series of market segments."
To learn more about how the DEB technology platform is powering a new frontier in biomaterial innovation, visit here.
Welcome to IFF
At IFF (NYSE: IFF), an industry leader in food, beverage, health, biosciences and scent, science and creativity meet to create essential solutions for a better world – from global icons to unexpected innovations and experiences. With the beauty of art and the precision of science, we are an international collective of thinkers who partners with customers to bring scents, tastes, experiences, ingredients and solutions for products the world craves. Together, we will do more good for people and planet. Learn more at iff.com, X (Twitter) , Facebook, Instagram, and LinkedIn.
©2023 International Flavors & Fragrances Inc. (IFF). IFF, the IFF Logo, and all trademarks and service marks denoted with TM, SM or ® are owned by IFF or affiliates of IFF unless otherwise noted. All Rights Reserved.
Contact:
Brenda Heffelfinger
VP of Marketing and Commercial Excellence, Health & Biosciences
+1 609 504 9979
brenda.heffelfinger@iff.com
SOURCE IFF
FAQ
What is the latest collaboration announced by IFF and Kemira?
When will the new biomanufacturing facility be operational?
What does the collaboration address in Kemira's growing demand?
What does IFF's DEB technology enable?
What is the aim of the collaboration with Chemigate?
